Cancer subclonal genetic architecture as a key to personalized medicine
- PMID: 24403863
- PMCID: PMC3884532
- DOI: 10.1593/neo.131972
Cancer subclonal genetic architecture as a key to personalized medicine
Abstract
The future of personalized oncological therapy will likely rely on evidence-based medicine to integrate all of the available evidence to delineate the most efficacious treatment option for the patient. To undertake evidence-based medicine through use of targeted therapy regimens, identification of the specific underlying causative mutation(s) driving growth and progression of a patient's tumor is imperative. Although molecular subtyping is important for planning and treatment, intraclonal genetic diversity has been recently highlighted as having significant implications for biopsy-based prognosis. Overall, delineation of the clonal architecture of a patient's cancer and how this will impact on the selection of the most efficacious therapy remain a topic of intense interest.
Similar articles
-
The Future of Precision Medicine in Oncology.Clin Lab Med. 2016 Sep;36(3):557-73. doi: 10.1016/j.cll.2016.05.003. Clin Lab Med. 2016. PMID: 27514468 Review.
-
Developing precision medicine in a global world.Clin Cancer Res. 2014 Mar 15;20(6):1419-27. doi: 10.1158/1078-0432.CCR-14-0091. Clin Cancer Res. 2014. PMID: 24634465 Free PMC article. Review.
-
Molecular Pathology: A Requirement for Precision Medicine in Cancer.Oncol Res Treat. 2016;39(12):804-810. doi: 10.1159/000453085. Epub 2016 Nov 25. Oncol Res Treat. 2016. PMID: 27889782 Review.
-
One mouse, one patient paradigm: New avatars of personalized cancer therapy.Cancer Lett. 2014 Mar 1;344(1):1-12. doi: 10.1016/j.canlet.2013.10.010. Epub 2013 Oct 22. Cancer Lett. 2014. PMID: 24157811 Free PMC article. Review.
-
[Precision Oncology: Approaching the Target].Dtsch Med Wochenschr. 2017 Nov;142(22):1637. doi: 10.1055/s-0043-114489. Epub 2017 Oct 27. Dtsch Med Wochenschr. 2017. PMID: 29078208 German. No abstract available.
Cited by
-
Evaluation of the Anti-Inflammatory and Anti-Oxidative Effects of Therapeutic Human Lactoferrin Fragments.Front Bioeng Biotechnol. 2021 Nov 30;9:779018. doi: 10.3389/fbioe.2021.779018. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 34917601 Free PMC article.
-
Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells.Transl Oncol. 2014 Dec;7(6):702-11. doi: 10.1016/j.tranon.2014.09.002. Transl Oncol. 2014. PMID: 25500079 Free PMC article.
-
PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.Neoplasia. 2014 Aug;16(8):634-43. doi: 10.1016/j.neo.2014.07.010. Neoplasia. 2014. PMID: 25220591 Free PMC article.
References
-
- Agudelo-Garcia PA, De Jesus JK, Williams SP, Nowicki MO, Chiocca EA, Liyanarachchi S, Li PK, Lannutti JJ, Johnson JK, Lawler SE, et al. Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. Neoplasia. 2011;13:831–840. - PMC - PubMed
-
- Berdiel-Acer M, Bohem ME, Lopez-Doriga A, Vidal A, Salazar R, Martinez-Iniesta M, Santos C, Sanjuan X, Villanueva A, Mollevi DG. Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death. Neoplasia. 2011;13:931–946. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources